Relmada Therapeutics Inc (RLMD)
0.452
-0.02
(-4.76%)
USD |
NASDAQ |
Jan 08, 16:00
0.452
0.00 (0.00%)
After-Hours: 04:23
Relmada Therapeutics SG&A Expense (Quarterly): 11.86M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.100B |
| Equillium Inc | 3.278M |
| Sensei Biotherapeutics Inc | 3.186M |
| NovaBay Pharmaceuticals Inc | 2.65M |
| Palatin Technologies Inc | 2.021M |